First participant dosed in Phase 1 clinical trial of EQ504, proof-of-mechanism data expected in Q2 2027
Cash equivalents of
Cash runway expected into 2029
“We continue to make important progress advancing EQ504, with the recent initiation of clinical development marking a significant milestone for the program,” said
Recent Corporate and Clinical Highlights:
Initiated Phase 1 clinical trial of EQ504
In
Milestone Closing of
On
Presented new nonclinical data further characterizing EQ504’s effects on epithelial barrier repair and immune regulation
Data presented at the 7th
Third Quarter 2026 Financial Results:
Cash and cash equivalents totaled
Research and development (R&D) expenses for the third quarter of 2026 were
General and administrative (G&A) expenses for the third quarter of 2026 were
Net loss for the third quarter of 2026 was
About EQ504
EQ504 is an investigational potent and selective aryl hydrocarbon receptor (AhR) modulator with a multi-modal immunoregulatory mechanism of action without broad immune suppression, designed to be complementary to other inflammation and immunology agents. AhR is critical to barrier organ tissue physiology and immunology, maintaining barrier function and promoting tissue repair and regeneration, while regulating resident immune cells with anti-inflammatory responses. For ulcerative colitis, EQ504 is formulated as an oral, colon-targeted delayed-release drug product.
About Equillium
Equillium is a biotechnology innovator with a mission to develop highly impactful therapies to treat serious autoimmune and inflammatory disorders. For more information, visit www.equilliumbio.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future”, “potential”, “will”, “designed to” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements include, but are not limited to, statements regarding Equillium’s plans and strategies with respect to developing EQ504, including the initiation of clinical studies and the reporting of data therefrom; the expected timeline for reporting data from the Phase 1 study of EQ504; the potential benefits of EQ504, including its potential ability to address key epithelial and immune pathways involved in inflammatory disease; the anticipated initiation of a placebo-controlled proof-of-concept study, or the expected timeline for initiating such study, in patients with ulcerative colitis; the expected use of proceeds from the Milestone Closing; and Equillium’s expectations that its financial position and cash runway is sufficient to fund its currently planned operations into 2029. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium’s ability to execute its plans and strategies; risks related to performing clinical and nonclinical studies; risks associated with relying on pro forma financial information; whether the results from clinical and nonclinical studies will validate and support the safety and efficacy of Equillium’s product candidates; changes in the competitive landscape; and Equillium’s ability to raise sufficient financing, which may not be available on acceptable terms or at all, to advance EQ504 and fund Equillium’s strategic plans. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission’s website and on Equillium’s website under the heading “Investors.” Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Investor Contact
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
| Condensed Consolidated Balance Sheets | |||||||
| (In thousands) | |||||||
| (unaudited) | |||||||
| 2026 | 2025 | ||||||
| Assets | |||||||
| Cash and cash equivalents | $ | 53,322 | $ | 30,277 | |||
| Prepaid expenses and other assets | 1,818 | 952 | |||||
| Operating lease right-of-use assets | 671 | 658 | |||||
| Total assets | $ | 55,811 | $ | 31,887 | |||
| Current liabilities | |||||||
| Accounts payable and other current liabilities | $ | 2,819 | $ | 2,934 | |||
| Total current liabilities | 2,819 | 2,934 | |||||
| Long-term operating lease liabilities | 313 | 356 | |||||
| Total liabilities | 3,132 | 3,290 | |||||
| Total stockholders' equity | 52,679 | 28,597 | |||||
| Total liabilities and stockholders' equity | $ | 55,811 | $ | 31,887 | |||
| Condensed Consolidated Statements of Operations | |||||||||||||||||
| (In thousands, except share and per share data) | |||||||||||||||||
| (unaudited) | |||||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||
| Operating expenses: | |||||||||||||||||
| Research and development | $ | 2,488 | $ | 1,301 | $ | 8,228 | $ | 11,307 | |||||||||
| General and administrative | 2,560 | 3,274 | 7,585 | 8,365 | |||||||||||||
| Total operating expenses | 5,048 | 4,575 | 15,813 | 19,672 | |||||||||||||
| Loss from operations | (5,048 | ) | (4,575 | ) | (15,813 | ) | (19,672 | ) | |||||||||
| Total other income, net | 465 | 345 | 1,226 | 1,049 | |||||||||||||
| Net loss | $ | (4,583 | ) | $ | (4,230 | ) | $ | (14,587 | ) | $ | (18,623 | ) | |||||
| Net loss per share, basic and diluted | $ | (0.04 | ) | $ | (0.06 | ) | $ | (0.14 | ) | $ | (0.41 | ) | |||||
| Weighted-average number of common shares outstanding, basic and diluted | 111,923,380 | 65,322,753 | 106,726,715 | 45,651,900 | |||||||||||||
Source: 